WallStreetZenWallStreetZen

NASDAQ: BBOT
Bridgebio Oncology Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BBOT

Based on 5 analysts offering 12 month price targets for Bridgebio Oncology Therapeutics Inc

Min Forecast
$22.00+157.01%
Avg Forecast
$24.80+189.72%
Max Forecast
$29.00+238.79%

Should I buy or sell BBOT stock?

Based on 5 analysts offering ratings for Bridgebio Oncology Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BBOT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BBOT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their BBOT stock forecasts and price targets.

BBOT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-08
lockedlocked$00.00+00.00%2026-06-22
lockedlocked$00.00+00.00%2026-05-11
lockedlocked$00.00+00.00%2026-03-06
lockedlocked$00.00+00.00%2026-02-11

1 of 1

Forecast return on equity

Is BBOT forecast to generate an efficient return?

Company
-45.03%
Industry
90.73%
Market
171.48%
BBOT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BBOT forecast to generate an efficient return on assets?

Company
-40.14%
Industry
27.24%
BBOT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BBOT earnings per share forecast

What is BBOT's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$2.28
Avg 2 year Forecast
-$2.22
Avg 3 year Forecast
-$2.30

BBOT revenue forecast

What is BBOT's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BBOT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BBOT$8.56$24.80+189.72%Strong Buy
SPRY$7.00$27.00+285.71%Strong Buy
OMER$9.69$34.50+256.04%Strong Buy
SGP$19.77$45.00+127.62%Strong Buy
CRMD$8.42$14.67+74.19%Buy
View Top Biotech Stocks

Bridgebio Oncology Therapeutics Stock Forecast FAQ

Is Bridgebio Oncology Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: BBOT) stock is to Strong Buy BBOT stock.

Out of 5 analysts, 3 (60%) are recommending BBOT as a Strong Buy, 2 (40%) are recommending BBOT as a Buy, 0 (0%) are recommending BBOT as a Hold, 0 (0%) are recommending BBOT as a Sell, and 0 (0%) are recommending BBOT as a Strong Sell.

If you're new to stock investing, here's how to buy Bridgebio Oncology Therapeutics stock.

What is BBOT's earnings growth forecast for 2026-2028?

(NASDAQ: BBOT) Bridgebio Oncology Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.33%.

Bridgebio Oncology Therapeutics's earnings in 2026 is -$154,095,000.On average, 13 Wall Street analysts forecast BBOT's earnings for 2026 to be -$182,483,983, with the lowest BBOT earnings forecast at -$197,047,454, and the highest BBOT earnings forecast at -$171,589,417. On average, 12 Wall Street analysts forecast BBOT's earnings for 2027 to be -$177,845,782, with the lowest BBOT earnings forecast at -$219,813,893, and the highest BBOT earnings forecast at -$145,178,105.

In 2028, BBOT is forecast to generate -$184,094,136 in earnings, with the lowest earnings forecast at -$222,169,042 and the highest earnings forecast at -$132,897,686.

What is BBOT's revenue growth forecast for 2026-2028?

(NASDAQ: BBOT) Bridgebio Oncology Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.93%.

Bridgebio Oncology Therapeutics's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast BBOT's revenue for 2026 to be $0, with the lowest BBOT revenue forecast at $0, and the highest BBOT revenue forecast at $0. On average, 11 Wall Street analysts forecast BBOT's revenue for 2027 to be $0, with the lowest BBOT revenue forecast at $0, and the highest BBOT revenue forecast at $0.

In 2028, BBOT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BBOT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BBOT) forecast ROA is -40.14%, which is lower than the forecast US Biotechnology industry average of 27.24%.

What is BBOT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year BBOT price target, the average BBOT price target is $24.80, with the highest BBOT stock price forecast at $29.00 and the lowest BBOT stock price forecast at $22.00.

On average, Wall Street analysts predict that Bridgebio Oncology Therapeutics's share price could reach $24.80 by Jul 8, 2027. The average Bridgebio Oncology Therapeutics stock price prediction forecasts a potential upside of 189.72% from the current BBOT share price of $8.56.

What is BBOT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BBOT) Bridgebio Oncology Therapeutics's current Earnings Per Share (EPS) is -$575.31. On average, analysts forecast that BBOT's EPS will be -$2.28 for 2026, with the lowest EPS forecast at -$2.46, and the highest EPS forecast at -$2.14. On average, analysts forecast that BBOT's EPS will be -$2.22 for 2027, with the lowest EPS forecast at -$2.74, and the highest EPS forecast at -$1.81. In 2028, BBOT's EPS is forecast to hit -$2.30 (min: -$2.77, max: -$1.66).

What is BBOT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BBOT) forecast ROE is -45.03%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.